ArticleInternational journal of molecular sciences2025
The Effect of Glucocorticoid and Mineralocorticoid Receptor Antagonists in the Skin of Aged Female Mice.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) are ligand-activated transcription factors that regulate epidermal homeostasis, inflammation, and function. Prior studies using epidermal-specific conditional single and double knockout mice have shown their importance in skin physiology; however, clinically human disease is largely treated pharmacologically. Our objective was to examine how systemic MR/GR antagonism affects cutaneous gene expression and epidermal thickness in aged (18-month-old) C57BL/6J female mice. Mice were treated with selective GR (relacorilant), selective MR (eplerenone), or dual GR/MR (miricorilant) antagonists for 8 weeks. Quantitative RT-qPCR analysis of the skin showed that miricorilant significantly upregulated Sgk1, a GR/MR target. Miricorilant also increased the expression of keratinocyte differentiation markers and downregulated key inflammatory cytokines and Col3a1, a collagen subtype associated with tissue remodeling. Relacorilant suppressed Scnn1g, a subunit of the epithelial sodium channel. None of the antagonists significantly altered proliferation markers, epidermal thickness, or regulators of glucocorticoid activity. Our findings show that miricorilant downregulated inflammatory cytokines and increased differentiation marker expression without affecting epidermal thickness, suggesting its potential to treat inflammatory skin diseases. The results contrast with data from GR/MR knockout studies, highlighting the likely significance of receptor dynamics. Further studies of antagonist effects on receptor interactions with co-regulators appear warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.